An EVOLVE Meeting:
From Data to Decision Making in Metastatic
Breast Cancer
Tuesday, 13 May 2025
14:00 – 19:30 CEST
AGENDA
Time
Topic
Speakers
14:00
Welcome and introduction
Eduard Vrdoljak, Croatia
14:30
Maximising outcomes in mBC
Treatment landscape and unmet medical need in mBC
CDK4/6 inhibitors across broader patient populations
Is CT part of the clinical consideration in HER2-mBC?
What’s on the horizon for patients with HR+ mBC?
Panel Q&A
Treatment landscape and unmet medical need in mBC
CDK4/6 inhibitors across broader patient populations
Is CT part of the clinical consideration in HER2-mBC?
What’s on the horizon for patients with HR+ mBC?
Panel Q&A
Asya Konsulova, Bulgaria
Otto Metzger, United States
Magdolna Dank, Hungary
Natalija Dedić Plavetić, Croatia
All
Otto Metzger, United States
Magdolna Dank, Hungary
Natalija Dedić Plavetić, Croatia
All
15:20
The importance of RWE today
Essentials of RWE and realising its potential for decision making Translating data into real-world value
RWE: A pros and cons debate
Panel Q&A
Essentials of RWE and realising its potential for decision making Translating data into real-world value
RWE: A pros and cons debate
Panel Q&A
Luis Castelo-Branco, Switzerland
Firmino Machado, Portugal
Lazar Popovic, Serbia
Jeliazko Arabadjiev, Bulgaria
All
Firmino Machado, Portugal
Lazar Popovic, Serbia
Jeliazko Arabadjiev, Bulgaria
All
16:35
Coffee Break
17:05
RWE: The totality of evidence or juggling many unknowns?
The increasing patient universe within RWE studies
Panel Q&A
The future of RWE: Emerging trends and opportunities
Panel Q&A
The increasing patient universe within RWE studies
Panel Q&A
The future of RWE: Emerging trends and opportunities
Panel Q&A
Hope Rugo, United States
All
Luis Castelo-Branco, Switzerland
All
All
Luis Castelo-Branco, Switzerland
All
18:30
Holistic view of RWE impact across CDK4/6-eligible populations
Elderly patients
Patients with visceral metastases
Subgroups with cardiovascular disorders
Impact of CDK4/6 inhibitors on real-world QoL
Panel Q&A
Elderly patients
Patients with visceral metastases
Subgroups with cardiovascular disorders
Impact of CDK4/6 inhibitors on real-world QoL
Panel Q&A
Simona Borštnar, Slovenia
Lyubov Simeonova, Bulgaria
Marijana Milović Kovačević, Serbia
Timur Cerić, Bosnia & Herzegovina
All
Lyubov Simeonova, Bulgaria
Marijana Milović Kovačević, Serbia
Timur Cerić, Bosnia & Herzegovina
All
19:20
Summary and close
Eduard Vrdoljak, Croatia
CDK4/6: cyclin-dependent kinases 4 and 6; CT: chemotherapy; HER2-: human epidermal growth factor receptor 2 negative; HR+: hormone receptor positive; mBC: metastatic breast cancer; RWE: real world evidence; Qol: quality of life.